Cannabidiol Counteracts Amphetamine-Induced Neuronal And Behavioral Sensitization Of The Mesolimbic Dopamine Pathway Through A Novel MTOR/p70S6 Kinase Signaling Pathway

Psychosis Schizophrenia Addiction to Methamphetamine

Key Findings

The cannabis-derived phytochemical, cannabidiol (CBD), has been shown to have pharmacotherapeutic efficacy for the treatment of schizophrenia. Our findings demonstrate a novel mechanism for the putative antipsychotic-like properties of CBD in the mesolimbic circuitry.

Information and Links


Link: Cannabidiol Counteracts Amphetamine-Induced Neuronal And Behavioral Sensitization Of The Mesolimbic Dopamine Pathway Through A Novel MTOR/p70S6 Kinase Signaling Pathway

Year: 2016

DOI: 10.1523/JNEUROSCI.3387-15.2016


Ratings

(How Ratings Work)

Psychosis — 2


Possible to probable range of efficacy of cannabis for treatment of Psychosis according to the results found in this study.

Schizophrenia — 2


Possible to probable range of efficacy of cannabis for treatment of Schizophrenia according to the results found in this study.

Addiction to Methamphetamine — 2


Possible to probable range of efficacy of cannabis for treatment of Addiction to Methamphetamine according to the results found in this study.

Drugs Used

Cannabidiol (CBD)